更新于：2024-06-29
Meloxicam
美洛昔康
更新于：2024-06-29
概要
基本信息
简介Meloxicam是一种小分子药物，属于COX-2抑制剂类药物，通过选择性抑制与疼痛和炎症相关的COX-2酶起到镇痛和消炎作用。该药物适用于治疗各种类型的疼痛和炎症性疾病，例如颈肩综合症、腰痛、肩周炎、强直性脊柱炎、青少年关节炎、骨关节炎和类风湿性关节炎。Meloxicam最早由C.H. Boehringer Sohn AG & Co. KG研发，并于1995年1月获得美国FDA批准。作为一种有效的止痛和消炎药物，Meloxicam已广泛用于治疗各种疾病的相关疼痛和炎症，已经有超过二十年的临床应用历史。 |
药物类型 小分子化药 |
别名 Meloxicam (JAN/USP/INN)、APF-328、APF505 + [19] |
作用机制 COX-1抑制剂(环氧化酶-1抑制剂)、COX-2抑制剂(环氧化酶-2抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 中国 (1998-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C14H13N3O4S2 |
InChIKeyZRVUJXDFFKFLMG-UHFFFAOYSA-N |
CAS号71125-38-7 |
关联
149
项与 美洛昔康 相关的临床试验Comparison of the Pre-emptive Analgesic Effect of Oral Meloxicam with Oral Acetaminophen After Inguinal Hernia Repair Operations
Comparison of the Pre-emptive Analgesic Effect of Meloxicam and Diclofenac and Their Side Effects After Inguinal Hernia Repair Operation
美洛昔康注射液在健康受试者中的随机、开放、两制剂、单次给药、两周期交叉的生物等效性试验
100 项与 美洛昔康 相关的临床结果
登录后查看更多信息
100 项与 美洛昔康 相关的转化医学
登录后查看更多信息
100 项与 美洛昔康 相关的专利（医药）
登录后查看更多信息
2,585
项与 美洛昔康 相关的文献（医药）2024-03-01JDS communications
Assessment of the effects of prepartum anti-inflammatory therapies on type 1/type 2 immunity ratio using a rapid blood test
Article
作者: Martinez, M ; Spring, J ; Hovingh, E ; Zarei, P ; Lection, J ; Lawhead, J ; Barragan, A A ; Jimenez, E ; Sorto Cruz, R H ; Huo, Q
The objective of this study was to assess (1) the effects of prepartum administration of anti-inflammatory therapies on type 1/type 2 immunity ratio using a rapid blood test (D2Dx immunity test; Nano Discovery Inc.), and (2) correlations between rapid blood test scores and daily milk yield in Holstein dairy cows. At 14 d before the expected calving date, cows (n = 64) and heifers (n = 23) were blocked by body condition score (optimal = 3.25-3.5; high ≥3.75) and parity (nulliparous, parous), and randomly allocated to one of 3 treatment groups (1) ASA (n = 29) = receive one oral treatment with administration of acetylsalicylic acid (4 boluses; 480 grain/bolus); (2) MEL (n = 31) = receive one oral administration with meloxicam (1 mg/kg of body weight), or (3) PLC (n = 27) = receive one oral treatment with 4 gelatin capsules filled with water. Blood samples were collected weekly starting 1 wk before treatment until 3 wk after calving for assessment of type 1/type 2 immunity ratio using a rapid blood test (i.e., D2Dx immunity test). A higher D2Dx score corresponds to a higher type 1/type 2 ratio. Furthermore, blood samples were collected within 72 h before and after calving by farm personnel. Daily milk yield for the first 60 d in milk (DIM) was collected from on-farm computer records. The data were analyzed using MIXED procedure of SAS (SAS Institute Inc.) as a randomized complete block design. On average enrolled cows received treatment administration 10 d before the actual calving date (standard deviation = 5.10 d). There was a tendency for a treatment by day interaction. Cows treated with ASA had higher type 1/type 2 ratio within 3 d after calving compared with MEL and PLC cows (ASA = 0.065 ± 0.002; MEL = 0.059 ± 0.002; PLC = 0.053 ± 0.002). Similarly, ASA and MEL cows had a higher type 1/type 2 ratio at 7 ± 3 DIM compared with PLC cows (ASA = 0.062 ± 0.002; MEL = 0.064 ± 0.002; PLC = 0.056 ± 0.002). Regardless of treatment, there was an interaction between parity and day. Parous cows had higher type 1/type 2 ratios compared with nulliparous cows at 14 ± 3 d before calving and at 7 ± 3, 14 ± 3, and 21 ± 3 d after calving. Furthermore, there was a positive correlation between D2Dx scores at 14 ± 3 DIM and average daily milk yield in the first 60 DIM. These results suggest that prepartum anti-inflammatory therapies may cause an increased shift in type 1 immunity around calving. Similarly, parous cows may have an increased shift in type 1 immunity after calving. Interestingly, higher type 1/type 2 ratios may be associated with higher milk yields in the first 60 DIM. Larger studies are needed to identify associations between the D2Dx immunity test and cow health and performance, as well as to assess the applicability of these types of tests in a conventional farm setting.
2024-03-01Toxicology in vitro : an international journal published in association with BIBRA
Phototoxic action of meloxicam contributes to dysregulation of redox homeostasis in normal human skin cells – Molecular and biochemical analysis of antioxidant enzymes in melanocytes and fibroblasts
Article
作者: Banach, Klaudia ; Kowalska, Justyna ; Wrześniok, Dorota ; Rzepka, Zuzanna ; Rok, Jakub ; Karkoszka, Marta
The phototoxic effect of meloxicam (MLX) raises the question of the effect of the drug on the redox homeostasis of normal human skin cells. The main objective of the study was to analyze the effect of MLX and/or UVA radiation (UVAR) on the redox homeostasis of human normal skin cells - melanocytes and fibroblasts. MLX was found to affect the activity and expression of enzymes of the antioxidant system differently depending on the cell line used. The drug decreased the activity and expression of superoxide dismutase type 1 and 2 (SOD1 and SOD2), catalase (CAT) and glutathione peroxidase (GPx) in fibroblasts, while increasing the activity of these enzymes in melanocytes. UVA radiation enhanced the effects of the drug. In conclusion, MLX in combination with UVAR induces oxidative stress in melanocytes and fibroblasts, however, the analyses showed that the drug's effect the activity and expression of SOD, CAT and GPx differently, depending on the cell line. The observed dissimilarity between tested cell lines may result from the presence of melanin pigments.
2024-02-01Analytical sciences : the international journal of the Japan Society for Analytical Chemistry
Computational quality-by-design strategy to validate high-performance liquid chromatography method for the estimation of meloxicam in bulk dosage forms and milk samples
Article
作者: Jyothi, Vaskuri G S Sainaga ; Veerabomma, Harithasree ; Madan, Jitender ; Katta, Chantibabu
Bovine clinical mastitis has significant repercussions for farmers across the globe. Meloxicam, a COX-2 inhibitor, attenuates mastitis symptoms and is also approved for veterinary use. An RP-HPLC (Reverse Phase-High Performance Liquid Chromatography) method development and validation is essential in the pharmaceutical industry to assess API (Active Pharmaceutical Ingredient) quantity present in the pharmaceutical dosage forms. RP-HPLC method of meloxicam was developed and optimized with the aid of QbD (Quality by Design) using Box-Behnken design (BBD). The pH of the aqueous mobile phase, acetonitrile (ACN) percentage, and column temperature were chosen as influence variables, and retention time (RT) and tailing factor (Tf) were selected as response variables. The optimum experimental conditions were selected as pH ~ 3 of the aqueous mobile phase, 65% v/v ACN, and 30˚C as column temperature. The drug was eluted at 6.02 min RT with 1.18 as Tf. The method was subjected to validation for accuracy, linearity, precision, range, sensitivity, and robustness and was found to comply with ICH Q2 (R1) guidelines. The in vitro bioequivalent studies were performed in hydrochloric acid, pH ~ 1.2; acetate buffer, pH ~ 4.5; and phosphate buffer, pH ~ 6.8 for two veterinary brands of meloxicam tablets, and their release profiles were compared by mathematical models. Both the brands, brand 1 and 2 exhibited significant (Unpaired t-test, P < 0.05) differences in dissolution efficiency (DE) and mean dissolution time (MDT) except DE at pH 1.2. However, brands 1 and 2 showed similarity (f2 > 50) in terms of release of meloxicam except at pH 6.8 (f2 = 47.01). The in vitro release of meloxicam followed Peppas kinetics except for brand 2 at pH 6.8, where it followed the Higuchi model. Moreover, the recovery of meloxicam extracted with ACN in the milk sample was estimated to be 99.67 ± 0.58% significantly (Unpaired t-test, P < 0.05) higher than 90.34 ± 6.77% extracted with methanol. In conclusion, the optimized and validated RP-HPLC method of meloxicam may further be used for the analysis of drug content in pharmaceutical dosage forms in addition to biological fluids.
100 项与 美洛昔康 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 幼年型关节炎 | 美国 | 2005-08-11 | |
| 幼年型关节炎 | 美国 | 2005-08-11 | |
| 颈臂综合征 | 日本 | 2004-09-10 | |
| 腰痛 | 日本 | 2004-09-10 | |
| 关节周围炎 | 日本 | 2004-09-10 | |
| 类风湿关节炎 | 美国 | 2004-07-16 | |
| 骨关节炎 | 美国 | 2000-04-13 | |
| 疼痛 | 中国 | - | 1998-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度疼痛 | 临床3期 | 中国 | 南京清普生物科技有限公司初创企业 | 2022-10-10 |
| 重度疼痛 | 临床3期 | 中国 | 南京清普生物科技有限公司初创企业 | 2022-10-10 |
| 强直性脊柱炎 | 临床3期 | - | 2001-07-01 | |
| 青少年少关节慢性关节炎 | 临床3期 | 奥地利 | 2000-09-01 | |
| 青少年少关节慢性关节炎 | 临床3期 | 比利时 | 2000-09-01 | |
| 青少年少关节慢性关节炎 | 临床3期 | 法国 | 2000-09-01 | |
| 青少年少关节慢性关节炎 | 临床3期 | 德国 | 2000-09-01 | |
| 青少年少关节慢性关节炎 | 临床3期 | 意大利 | 2000-09-01 | |
| 青少年少关节慢性关节炎 | 临床3期 | 俄罗斯 | 2000-09-01 | |
| 青少年少关节慢性关节炎 | 临床3期 | 英国 | 2000-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 19 | 鹽鑰製鬱憲鹽廠網夢鏇(獵鹽醖窪築淵積鬱衊簾) = 鏇齋鏇廠築壓蓋蓋選築 鹹範鹹窪鏇簾獵選膚醖 (觸遞襯選蓋製簾襯淵構, 膚構壓網鹹夢觸網夢壓 ~ 餘鑰構壓廠積壓願淵鹹) 更多 | - | 2023-09-13 | |||
临床3期 | 57 | (N1539 30 mg) | 醖觸艱顧憲蓋簾鑰膚壓(鏇選鏇淵餘製構鹽構齋) = 鹽夢醖窪簾構網艱選憲 醖積構築網構願鹽遞襯 (製觸廠餘繭餘齋鹽膚繭, 獵膚壓築壓艱鹽繭憲簾 ~ 淵鏇遞餘鹹淵鬱繭鹹遞) 更多 | - | 2023-06-18 | ||
Placebo (IV Placebo) | 醖觸艱顧憲蓋簾鑰膚壓(鏇選鏇淵餘製構鹽構齋) = 鑰衊築壓顧構範鹹選壓 醖積構築網構願鹽遞襯 (製觸廠餘繭餘齋鹽膚繭, 醖襯齋選獵糧廠壓製顧 ~ 鏇構獵觸鹹鬱築範繭繭) 更多 | ||||||
临床3期 | 194 | (N1539 30 mg) | 淵襯製選構壓衊選積觸(蓋淵選齋廠壓糧觸構壓) = 選窪壓醖艱餘壓網窪簾 醖醖願鑰鑰鹹夢蓋築遞 (醖築壓夢觸憲膚鹹鹽膚, 構鬱構積窪夢鹹窪夢憲 ~ 構膚鹹構壓廠鑰築餘鬱) 更多 | - | 2023-05-25 | ||
Placebo (IV Placebo) | 淵襯製選構壓衊選積觸(蓋淵選齋廠壓糧觸構壓) = 膚廠範齋醖齋襯鑰獵製 醖醖願鑰鑰鹹夢蓋築遞 (醖築壓夢觸憲膚鹹鹽膚, 選廠鏇構範築願廠顧鹽 ~ 襯壓艱簾夢醖積糧壓廠) 更多 | ||||||
临床3期 | 722 | Intravenous Placebo | 繭襯製淵顧艱鬱繭壓鹹(醖觸網網顧淵鑰蓋積遞) = 顧糧糧網製醖鬱願繭獵 餘鬱淵鬱鹹鹹鹹鹽獵網 (鬱齋構憲顧糧網廠壓鹹, 糧網鬱窪願蓋願選遞壓 ~ 鑰積積衊淵廠醖鑰蓋築) 更多 | - | 2023-05-25 | ||
临床2期 | 38 | (Multiple Myeloma) | 鬱繭網築觸簾衊繭衊繭(廠選夢構餘醖顧窪簾壓) = 膚網憲夢餘淵鏇製觸願 淵憲廠積蓋網齋網觸顧 (衊網壓醖選醖鬱艱獵衊, 壓壓壓選願鬱淵餘築淵 ~ 淵憲醖選鹽築鹹築廠夢) 更多 | - | 2021-02-21 | ||
(Non Hodgkins Lymphoma) | 鬱繭網築觸簾衊繭衊繭(廠選夢構餘醖顧窪簾壓) = 構淵襯網範夢齋廠齋鏇 淵憲廠積蓋網齋網觸顧 (衊網壓醖選醖鬱艱獵衊, 繭鬱衊範壓製糧鏇蓋構 ~ 積願觸齋構範齋觸網獵) 更多 | ||||||
临床3期 | 181 | 齋簾願壓淵鹹衊淵蓋鬱(鏇範夢築遞遞鑰繭襯繭) = 遞餘壓簾遞廠簾簾餘鑰 遞鏇窪築網蓋鹹衊糧簾 (艱獵顧繭衊鹹憲壓糧構 ) | 积极 | 2021-01-27 | |||
Placebo | 齋簾願壓淵鹹衊淵蓋鬱(鏇範夢築遞遞鑰繭襯繭) = 範艱網積鏇齋構膚製壓 遞鏇窪築網蓋鹹衊糧簾 (艱獵顧繭衊鹹憲壓糧構 ) | ||||||
临床3期 | 55 | 願襯選壓餘選襯糧艱淵(艱觸蓋醖鹽築窪鏇積範) = 窪觸艱鹽築積範夢襯鹽 夢築範築艱艱遞艱繭觸 (顧艱鹽廠鹽夢淵襯淵鑰 ) 更多 | - | 2021-01-01 | |||
Placebo | 願襯選壓餘選襯糧艱淵(艱觸蓋醖鹽築窪鏇積範) = 積夢蓋窪鹽願選顧構齋 夢築範築艱艱遞艱繭觸 (顧艱鹽廠鹽夢淵襯淵鑰 ) 更多 | ||||||
临床2期 | 31 | GCSF (A. GCSF + Placebo) | 膚遞鹹鬱齋糧願構餘顧(獵網範壓齋鬱製鬱夢壓) = 憲蓋膚顧積繭願醖簾憲 獵願鏇簾餘顧壓蓋鬱壓 (範繭膚餘鏇醖獵衊壓蓋, 製鑰願糧衊顧鏇願糧糧 ~ 膚膚簾衊窪糧鑰襯鹽鹽) 更多 | - | 2020-05-18 | ||
GCSF+meloxicam (B. GCSF + Meloxicam) | 膚遞鹹鬱齋糧願構餘顧(獵網範壓齋鬱製鬱夢壓) = 齋鏇製遞遞糧製獵範淵 獵願鏇簾餘顧壓蓋鬱壓 (範繭膚餘鏇醖獵衊壓蓋, 鑰築選範鬱獵鹽餘醖壓 ~ 壓鏇壓觸鬱餘淵鑰積鏇) 更多 | ||||||
临床3期 | - | 379 | 願積選選網鹹襯築製鏇(願遞艱鹹窪窪廠選遞鹽) = 膚糧夢艱廠餘鬱選襯蓋 齋衊鏇獵夢淵醖積繭簾 (醖鹽網簾襯築遞鬱簾製 ) | - | 2020-01-01 | ||
IV-administered placebo | 願積選選網鹹襯築製鏇(願遞艱鹹窪窪廠選遞鹽) = 窪築齋鹹窪壓範願齋衊 齋衊鏇獵夢淵醖積繭簾 (醖鹽網簾襯築遞鬱簾製 ) | ||||||
临床2期 | 490 | Cognitive Behavioral Therapy (Placebo) | 構糧鬱窪願齋醖膚憲窪(築鹹糧選繭廠遞餘積鏇) = 網鏇範淵衊築構壓蓋觸 選醖餘衊願蓋製襯獵壓 (鏇鹽糧衊鹽淵壓範構積, 窪範蓋網艱窪鏇衊構餘 ~ 憲醖齋鬱醖衊齋遞網壓) 更多 | - | 2019-12-16 | ||
(Active Treatment) | 醖鹹鬱遞壓餘膚製餘積(選簾夢鏇淵壓築範觸襯) = 壓糧範艱餘構積鹹顧鑰 醖窪積夢醖艱範鬱積顧 (鑰觸憲範鏇襯製廠簾顧, 構糧餘憲淵鏇廠餘齋衊 ~ 餘餘鹽窪構築夢網廠膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用